In this presentation, we will discuss two enzymatic approaches for siRNA synthesis that are commercially relevant to address the foreseeable market demands. First, a ligation method utilizing engineered dsRNA ligases to enable assembly of crude shortmer oligos synthesized by SPOS. Second, a polymerase-based oligonucleotide synthesis technology for the linear, stepwise manufacturing of siRNA therapeutics assets.